Latest News
Guardant Health, Inc.
- Guardant Health, Inc. Estimates – NASDAQ:GH
- Form 4 Guardant Health Inc: Roberto Mignone (Director) For: 21 October
- Guardant Health to Highlight Advances in Liquid Biopsy for Cancer Monitoring at ESMO 2026
- ETFs Investing in Guardant Health, Inc. Stocks
- TwinStrand, UW notch another legal victory in patent dispute with Guardant Health
- Guardant Health (NDQ:GH): The Company Betting Its Cancer Screening Method Will Be Revolutionary!
- Guardant Health Announces Approval In Europe Of Guardant360® Cdx
- Guardant Health receives European approval for breast cancer test
- Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250
- Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know
- Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
- Guardant Health co-CEO Helmy Eltoukhy on breast cancer test
Headlines from the last 30 days, linking to the original publishers. See all market news →